Trial
NCT05829434
Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS
Phase IIWITHDRAWNSAFETYConfidence: HIGH
Sponsor
Uwe Platzbecker
Collaborators
Gilead Sciences
Condition
Acute Myeloid Leukemia
Intervention
Magrolimab
Why stopped
Trial was stopped prematurely due to safety reasons
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-02-12